慢性リンパ球性白血病患者の遺伝子組み換え毒素 (DAB486IL-2) の治療効果
C F LeMaistre1, M G Rosenblum, J M Reuben
1Department of Medicine/Hematology, University of Texas Health Science Center, San Antonio 78284-7880.
Lancet (London, England)
|May 11, 1991
まとめ
融合タンパク質であるDAB486IL-2は,高親和性IL-2受容体を持つ癌細胞を標的とする. 他の治療に耐性のある慢性リンパ球性白血病の患者が,この新しい治療法に対して肯定的な反応を示しました.
科学分野:
- バイオテクノロジー バイオテクノロジー
- 腫瘍学 腫瘍学
- 免疫学 免疫学とは
背景:
- ディフテリア毒素は強力な細胞毒素です.
- インタールイキン-2 (IL-2) 受容体は,特定の白血病細胞で高度に発現します.
- 標的型がん治療は,悪性細胞を選択的に排除することを目的としています.
さらに関連する動画
08:17A Human Peripheral Blood Mononuclear Cell (PBMC) Engrafted Humanized Xenograft Model for Translational Immuno-oncology (I-O) Research
Published on: August 15, 2019
08:05Bone Marrow Transplantation Platform to Investigate the Role of Dendritic Cells in Graft-versus-Host Disease
Published on: March 17, 2020
関連する概念動画
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...